—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Fagron NV (FAGR.BR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for FAGR.BR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in Europe: −1.2% week · −3.2% month · −6.1% quarter · +2.3% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against FAGR.BR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Fagron NV

FAGR.BR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Fagron NV compounds and personalises pharmaceutical treatments for hospitals, pharmacies, clinics and patients worldwide, working through three segments: Essentials, Brands and Compounding Services. Its product range spans capsule and tablet excipients, dermatology and scar-care formulations, hair-loss treatments and a paediatric suspension base, alongside training for prescribers and pharmacists through its own academy. The company, formerly named Arseus, is based in Nazareth, Belgium.
Where it sits in the stack
Fagron carries no seat in our index and sits outside the AI build-out entirely; it belongs to the healthcare sleeve of our universe, under drug manufacturing for specialty and generic products, where compounding rather than mass production is the business.
Who it is priced against
Closelooknet's peer group has no entry for Fagron, so no comparison set or reasoning is on file here.
Why Closelooknet tracks it
Fagron holds no seat in any Closelooknet index, carries no score, and appears in none of the diary's editions or quotes; the diary notes it only through its chart structure readings.
What the diary watches
Whether the balance between its Essentials, Brands and Compounding Services segments shifts, since a move toward higher-margin branded and dermatology lines would change how the business reads.

Fagron NV (FAGR.BR) trades on the BR exchange in Belgium, classified under Healthcare.

The Closelooknet company score reads 53/100 composite (momentum 47, quality 57, valuation 60) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 1.74%, annual · buybacks 4 m EUR in FY2025

Dividends and capital return

What FAGR.BR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.40 EUR per share · a 1.74% yield on the 2026-10-06 close 1 distribution, paid once a year 2026-10-06
  • Change on the year +14.3% against the prior twelve months prior twelve months 0.35 EUR per share
  • Last distribution 0.40 EUR per share as the price series records it, within days of the ex-date 2026-05-18
  • By calendar year 2025: 0.35 EUR (partial) · 2026: 0.40 EUR to date first distribution recorded in the three-year window: 2025-05-19
  • Dividends paid, FY2025 26 m EUR 64% of earnings
  • Buybacks, FY2025 4 m EUR 0.2% of today's market value
  • Share count +0.6% in FY2025 1 m EUR of stock-based compensation in the year
  • Capital returned 30 m EUR · 27% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Fagron NV (FAGR.BR)?

Fagron NV trades as FAGR.BR on the BR exchange (Belgium) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is FAGR.BR in a Closelooknet index?

Not currently — Fagron NV is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Fagron NV's Closelooknet composite score?

53 out of 100, with momentum 47, quality 57 and valuation 60 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does FAGR.BR trade against its moving averages?

Recovery attempt under the 200-day: Trades +3.4% vs the 50-day and +1.5% vs the 200-day average, 8.9% below the 52-week high and +17.2% off the 52-week low; a death cross printed 12 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Fagron NV compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic), Fagron NV (FAGR.BR) sits 8.9% below its 52-week high, 3.4% above its 50-day average; Laboratorios Farmaceuticos ROVI (ROVI.MC) is 31.8% below, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is 4.2% below, Almirall S.A. (ALM.MC) is 26.2% below. Put any of them next to FAGR.BR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Fagron NV do?

Fagron NV compounds and personalises pharmaceutical treatments for hospitals, pharmacies, clinics and patients worldwide, working through three segments: Essentials, Brands and Compounding Services. Its product range spans capsule and tablet excipients, dermatology and scar-care formulations, hair-loss treatments and a paediatric suspension base, alongside training for prescribers and pharmacists through its own academy. The company, formerly named Arseus, is based in Nazareth, Belgium. Closelooknet's peer group has no entry for Fagron, so no comparison set or reasoning is on file here.

Where does Fagron NV sit in the AI build-out?

Fagron carries no seat in our index and sits outside the AI build-out entirely; it belongs to the healthcare sleeve of our universe, under drug manufacturing for specialty and generic products, where compounding rather than mass production is the business. Fagron holds no seat in any Closelooknet index, carries no score, and appears in none of the diary's editions or quotes; the diary notes it only through its chart structure readings.

Does Fagron NV pay a dividend?

Fagron NV has paid 0.40 EUR per share over the last twelve months, paid once a year, a trailing yield of 1.74% on the 2026-10-06 close; the last distribution recorded in the price series was 0.40 EUR on 2026-05-18. In fiscal 2025 the company paid 26 m EUR in dividends and bought back 4 m EUR of its own shares, 27% of that year’s free cash flow. The share count rose 0.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for FAGR.BR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.